BC 025 – Efficacité de la canagliflozine chez les patients avec néphropathie diabétique (étude CREDENCE).

BaladoCritique - club de lecture médical

Dans cette 25e baladodiffusion, les Drs Gabriel Huard et Luc Lanthier discutent de l’effet d’un inhibiteur de la SGLT2, la canagliflozine sur le pronostic rénal des patients avec néphropathie diabétique, en plus de réviser la littérature médicale d’avril 2019.

Quiz clinique (2 min 08), étude principale (2 min 35), critique (19 min 56), autres articles (29 min 23), réponse au quiz clinique (32 min 45)

Référence principale

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019. doi: 10.1056/NEJMoa1811744. PubMed PMID: 30990260.

Articles associés

Ingelfinger JR, Rosen CJ. Clinical Credence – SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease.N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMe1904740. PubMed PMID: 30990261.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. PubMed PMID: 28605608.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323-34. PubMed PMID: 27299675.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. PubMed PMID: 26378978.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57. PubMed PMID: 30415602.

Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019. doi: 10.7326/M19-0085. PubMed PMID: 31060053.

Autres articles d’intérêt

Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261-74. PubMed PMID: 30874766.

Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019;321(15):1466-80. PubMed PMID: 30903796.

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019;380(14):1326-35. PubMed PMID: 30730782.

Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS, et al. Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis. N Engl J Med. 2019;380(14):1305-15. PubMed PMID: 30779530.

Référence du quiz clinique

Wachterman MW et al. One-year mortality after dialysis initiation among older adults. JAMA Intern Med 2019 Apr 22. doi: 10.1001/jamainternmed.2019.0125. PubMed PMID: 31009039.